Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection

CONCLUSIONS: We are very uncertain about the effect of immunoglobulins on mortality. We are moderately certain that use of immunoglobulins in hospitalised infants and children may result in little to no difference in the length of hospitalisation. Immunoglobulins may result in little to no difference in adverse events, the need for or duration of mechanical ventilation, supplemental oxygen, or admission to the intensive care unit, though we are less certain about this evidence and the true effect of immunoglobulins on these outcomes may differ markedly from the estimated effect observed in this review. All trials were conducted in high-income countries, and data from populations in which the rate of death from RSV infection is higher are lacking.PMID:37870128 | DOI:10.1002/14651858.CD009417.pub3
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research